MAP1LC3A and viral infectious disease: As demonstrated in Fig. 6A and B, the percentage of cells containing EGFP-LC3 dots to cells expressing EGFP significantly (P<0.01) increased after virus infection (NC group) as compared with the blank group, whereas this percentage in the evodiamine-treatment (12.5 μg/mL) group significantly decreased as compared with the NC group.